Myoview (Tetrofosmin)

Tetrofosmin is a lipophilic cationic complex that distributes in proportion to regional myocardial blood flow. After intravenous injection, it enters viable heart cells and accumulates within mitochondria due to the negative membrane potential. The retained tracer emits gamma photons that are captured by SPECT cameras to produce detailed perfusion images.

The dose of Myoview is determined by the prescribing physician based on the specific imaging protocol, patient weight, and equipment calibration. A standard practice involves administering a calculated activity of the injectable solution intravenously shortly before the SPECT scan, but exact amounts are individualized and not disclosed here.

Safety data for Myoview in pregnancy and lactation are limited, and the product is classified as having an unknown risk. It should only be used when clearly needed and after a risk‑benefit assessment by the healthcare provider. Breastfeeding mothers should discuss potential risks with their clinician.

To order Myoview, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain if required), and any necessary import documentation.

Myoview (tetrofosmin) and technetium‑99m sestamibi are the most common SPECT myocardial perfusion tracers. Both provide high‑quality images, but tetrofosmin has slightly faster hepatic clearance, potentially reducing soft‑tissue interference. Choice often depends on local availability, imaging protocol, and physician preference.

Myoview must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. The vial should remain in its original packaging until use, and any unused portion must be discarded according to local radiopharmaceutical waste regulations.

Myoview is administered as an intravenous injection of the sterile injectable solution. The injection is performed by qualified personnel in a controlled environment, typically shortly before the SPECT imaging session. The exact timing and activity are defined by the imaging protocol prescribed by the physician.

The most serious risks include rare but severe allergic reactions such as anaphylaxis, sudden hypotension, and cardiac arrhythmias that may occur during or after injection. Immediate medical attention is required if any of these symptoms develop, and patients should be monitored according to standard nuclear medicine safety guidelines.

Myoview should be avoided in patients with known hypersensitivity to tetrofosmin or any component of the formulation. It is also contraindicated in individuals where the diagnostic benefit does not outweigh the potential risk, such as pregnant women without a clear indication, and in patients who have received other myocardial perfusion agents within a short interval that could compromise image quality.